Serotonin Receptor Modulators

Pathophysiology of the Enteric Nervous System: A Basis for Understanding Functional Diseases

Volumn , Issue , 2008, Pages 228-247

  De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Agonists; Functional dyspepsia; Gut motor disorders; Myenteric ganglia; Serotonin receptor modulators

Indexed keywords

EID: 84992738200     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470760307.ch18     Document Type: Chapter

References (138)

1. Vialli M, Erspamer V. Ricerche sul secreto delle cellule ente-rocromaffini. IX. Intorno alla natura chimica della sostanza specifica. Boll Soc Med Chir Pavia 1937; 51:1111-30.
2. Tonini M, De Ponti F. Serotonin modulation of gastrointestinal motility. In: Gaginella TS, Galligan JJ, eds. Serotonin and Gastrointestinal Function. Boca Raton: CRC Press, 1995: 53-84.
3. Biilbring E, Lin RCY. The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis: the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol (Land) 1958; 140: 381-98.
4. Biilbring E, Crema A. The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. J Physiol (Lond) 1959; 146: 18-28.
5. Biilbring E, Gershon MD. 5-hydroxytryptamine participation in the vagal inhibitory innervation of the stomach. J Physiol (Lond) 1967; 192: 23-6.
6. Glatt CE, Tampilic M, Christie C, DeYoung J, Freimer NB. Re-screening serotonin receptors for genetic variants identifies population and molecular genetic complexity. Am J Med Genet 2004; 124B: 92-100.
7. Linden DR, Chen JX, Gershon MD, Sharkey KA, Mawe GM. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am] Physiol 2003; 285: G207-16.
8. Coates MD, Mahoney CR, Linden DR et al. Molecular de-fects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and IBS. Gastroenterology 2004; 126: 1657-64.
9. Camilleri M, Atanasova E, Carlson PJ et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002;123:425-32.
10. Lo Briejer MR, Akkermans LM, Schuurkes JA. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631-51.
11. Read NW, Gwee KA. The importance of 5-hydroxytryptamine receptors in the gut. Pharmacol Ther 1994; 62: 159-73.
12. Galligan J J. Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. In: Gaginella TS, Galligan JJ, eds. Serotonin and Gastrointestinal Function. Boca Raton: CRC Press, 1995: 109-26.
13. Prins NH, Briejer MR, Van Bergen PJ, Akkermans LM, Schuurkes JA. Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle. Br J Pharmacol 1999; 128: 849-52.
14. Mawe GM, Branchek TA, Gershon MD. Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists. Proc Natl Acad Sci USA 1986; 83: 9799-803.
15. Hoyer D, Clarke DE, Fozard JR et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157-203.
16. Dietrich C, Kilbinger H. 5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanisms. Neuropharmacology 1996; 35: 483-8.
17. Kuemmerle JF, Murthy KS, Grider JR, Martin DC, Ma-khlouf GM. Coexpression of 5-HT2A and 5-HT4 receptors coupled to distinct signaling pathways in human intestinal muscle cells. Gastroenterology 1995; 109: 1791-800.
18. Malagelada JR. Review article: clinical pharmacology models of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13(Suppl.2): 57-64.
19. De Ponti F, Malagelada JR. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol Ther 1998; 80: 49-88.
20. Tuladhar BR, Kaisar M, Naylor RJ. Evidence for a 5-HT3 receptor involvement in the facilitation of peristalsis on mucosal application of 5-HT in the guinea pig isolated ileum. Br J Pharmacol 1997; 122: 1174-8.
21. Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999; 288: 93-7.
22. Miyata K, Kamato T, Nishida A et al. Pharmacologic profile of (R)-5-[(l-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahy-dro-lH-benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther 1991; 259: 15-21.
23. Messori E, Candura SM, Coccini T, Balestra B, Tonini M. 5-HT3 receptor involvement in descending reflex relaxation in the rabbit isolated distal colon. Eur J Pharmacol 1995; 286: 205-8.
24. Miyata K, Kamato T, Nishida A et al. Role of serotonin 3 receptor in stress-induced defecation. J Pharmacol Exp Ther 1992;261:297-303.
25. Kadowaki M, Nagakura Y, Tomoi M, Mori J, Kohsaka M. Effect of FK1052, a potent 5-hydroxytryptamine 3 and 5-hydroxytryptamine 4 receptor dual antagonist, on colonic function in vivo. J Pharmacol Exp Ther 1993; 266: 74-80.
26. Sakurai-Yamashita Y, Yamashita K, Yoshimura M, Taniyama K. Differential localization of 5-hydroxytryptamine 3 and 5-hydroxytryptamine 4 receptors in the human rectum. Life Sci 2000; 66:31-1.
27. Sakurai-Yamashita Y, Yamashita K et al. Differential distribution of 5-hydroxytryptamine 3 receptor in the colon between human and guinea pig. Chin J Physiol 1999; 42: 195-8.
28. Talley NT, Phillips SF, Haddad A et al. Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989; 34:1511-15.
29. Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992; 67: 732-8.
30. Talley NJ, Phillips SF, Haddad A et al. GR 38032F (ondansetron), a selective 5-HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 477-80.
31. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris Al. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Alim Pharmacol Ther 1990; 4: 139-44.
32. von der Ohe M, Hanson RB, Camilleri M. Serotonergic me- 1 diation of postprandial colonic tonic and phasic responses in humans. Gut 1994; 35: 536-11.
33. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syn-A drome and functional dyspepsia? Alim Pharmacol Ther 1996; 10: 595-9.
34. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor A antagonist, in patients with irritable bowel syndrome. Alim Pharmacol Ther 1993; 7: 175-80.
35. von der Ohe MR, Camilleri M, Kvols LK. A 5-HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994; 106: 1184-9.
36. Schuurkes JAJ, Meulemans AL, Obertop H, Akkermans LMA. 5-HT4 receptors on the human stomach [abstract]. J Gastrointest Motil 1991; 3: 199.
37. Sakurai-Yamashita Y, Takada K, Takemura K et al. Ability of mosapride to bind to 5-HT4 receptor in the human stomach. Jpn J Pharmacol 1999; 79:493-6.
38. Burleigh DE, Trout SJ. Evidence against an acetylcholine releasing action of cisapride in the human colon. Br] Clin Pharmacol 1985; 20: 475-8.
39. Borman RA, Burleigh DE. Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT. Br] Pharmacol 1993; 110:927-8.
40. Briejer MR, Akkermans LM, Meulemans AL, Lefebvre RA, Schuurkes JA. Cisapride and a structural analogue, R 76,186, are 5-hydroxytryptamine 4 (5-HT4) receptor agonists on the guinea-pig colon ascendens. Naunyn Schmiedebergs Arch Pharmacol 1993; 347:464-70.
41. Wardle KA, Sanger GJ. The guinea-pig distal colon - a sensitive preparation for the investigation of 5-HT4 receptor-mediated contractions. Br J Pharmacol 1993; 110: 1593-9.
42. Tarn FS, Hillier K, Bunce KT, Grossman C. Differences in response to 5-HT4 receptor agonists and antagonists of the 5-HT4-like receptor in human colon circular smooth muscle. Br J Pharmacol 1995; 115: 172-6.
43. McLean PG, Coupar IM. Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors. Br J Pharmacol 1996; 117: 238-9.
44. Prins NH, Akkermans LMA, Lefebvre RA, Cheyns P, Schuurkes JAJ. Cholinergic 5-HT4 receptor stimulation enhances canine and human colon longitudinal muscle contractility [abstract]. Neurogastroenterol Motil 2000; 12: 267.
45. Grider JR, Kuemmerle JF, Jin JG. 5-HT released by mucosal stimuli initiate peristalsis by activating 5-HT4/5-HTlp receptors on sensory CGRP neurons. Am J Physiol 1996; 270: 778-82.
46. Foxx-Orenstein AE, Kuemmerle JF, Grider JR. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea-pig intestine. Gastroenterology 1996; 111: 1281-90.
47. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryp-tamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370-80.
48. Tack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998; 12: 761-6.
49. Manes G, Dominguez-Munoz JE, Leodolter A, Malferthein-er P. Effect of cisapride on gastric sensitivity to distension, gastric compliance and duodeno-gastric reflexes in healthy humans. Dig Liver Dis 2001; 33:407-13.
50. Coelho AM, Rovira P, Fioramonti J, Buéno L. Antinociceptive properties of HTF919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats [abstract]. Gastroenterology 2000; 118 (Suppl. 2): A835.
51. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577-85.
52. Gunput MD. Review article: clinical pharmacology of alos-etron. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 70-6.
53. Humphrey PP, Bountra C, Clayton N, Kozlowski K. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 31-8.
54. Balfour JA, Goa KL, Perry CM. Alosetron [see Guest Commentaries]. Drugs 2000; 59: 511-18.
55. Kozlowski CM, Green A, Grundy D, Boissonade FM, Bountra C. The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46:474-80.
56. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexi-nos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55.
57. Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 869-78.
58. Moss HE, Sanger GJ. The effects of granisetron, ICS 205930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990; 100:497-501.
59. Miura M, Lawson DC, Clary EM, Mangel AW, Pappas TN. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci 1999; 44: 20-4.
60. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996; 57: 478-83.
61. Feinle C, Read NW. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol 1996; 261: G591-7.
62. Talley NJ, Van Zanten SV, Saez LR et al. A dose-ranging, pla- cebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 525-37.
63. Kuo B, Camilleri M, Burton D, Viramontes B et al. Effects of 5-HT3 antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 2002; 16: 225-33.
64. Zerbib F, Bruley Des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8:403-7.
65. Bardhan KD, Bodemar G, Geldof H et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 23-34.
66. Jones RH, Holtmann G, Rodrigo L et al. Alosetron relieves pain and improves bowel function compared with mebev-erine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419-27.
67. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
68. Cremonini F, Delgado-Aros S, CamilJeri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86.
69. Stacher G. Cilansetron. Solvay. Cwrr Opin Investig Drugs 2001; 2: 1432-6.
70. Stacher G, Weber U, Stacher-Janotta G et al. Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial. Br J Clin Pharmacol 2000; 49:429-36.
71. Clouse R.E., Caras S., Cataldi F., et al. Cilansetron is efficacious for relief of urgency in patients with irritable bowel syndrome with diarrhea predominance (IBS-D). JPGN 2004; 39 (Suppl. 3): S777.
72. Coleman NS, Marciani L, Blackshaw E et al. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther 2003; 18: 1039-48.
73. Tonini M, De Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics. Alim Pharmacol Ther 1999; 13: 1585-91.
74. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 277-89.
75. Wagstaff AJ, Frampton JE, Croom KF. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs 2003; 63: 1101-20.
76. Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1493-7.
77. Camilleri M, McKinzie S, Burton D, Thomforde GM, Zinsmeister A, Bouras EP. Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS) [abstract]. Gastroenterology 2000; 118(Suppl.2):A845.
78. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001; 61: 317-32.
79. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic pptential? J Pharmacol Exp Ther 1997; 282: 220-7.
80. Drici MD, Ebert SN, Wang WX et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999; 34: 82-8.
81. Whorwell PJ, Krumholz S, Muller-Lissner S, Schmitt C, Dunger-Baldauf C, Rueegg PC. Tegaserod has a favorable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome (IBS) [abstract]. Gastroenterology 2000; 118 (Suppl. 2):A1204.
82. Nguyen A, Camilleri M, Kost LJ et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997; 280: 1270-6.
83. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 682-6.
84. Emmanuel AV, Nicholls T, Roy AJ, Antonelli K, Kamm MA. Prucalopride (PRU) improves colonic transit and stool frequency in patients (pts) with slow and normal transit constipation [abstract]. Gastroenterology 2000; 118 (Suppl. 2): A846.
85. Yoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals [abstract!. Arzneimittelforschung 1993; 43: 1078-83.
86. Mine Y, Yoshikawa T, Oku S, Nagai R, Yoshida N, Hosoki K. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther 1997; 283: 1000-8.
87. Ruth M, Hamelin B, Rôhss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Alim Phar-macol Ther 1998; 12: 35-10.
88. Hallerback BI, Bommelaer G, Bredberg E et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002; 16: 959-67.
89. Degen L, Matzinger D, Merz M. Tegaserod (HTF919), a 5-HT4 receptor partial agonist, accelerates gastrointestinal transit. Gastroenterology 2000; 118: A845.
90. Tack J, Vos R, Janssens J, Salter J, Jauffret S, Vandeplassche G. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003; 18:1031-7.
91. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
92. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
93. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
94. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
95. Tougas G, Snape WJ Jr, Otten MH et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1701-8.
96. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42: 511-16.
97. Otten M, Schneider H, Wurzer H et al. A double-blind, placebo controlled evaluation of safety and efficacy of 12-week, twice-daily treatment with prucaloprid in patients with chronic constipation. Gastroenterology 1999; 116: 1055.
98. Sanger GJ, Banner SE, Smith MI, Wardle KA. SB-207266: 5-HT4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models. Neurogastroenterol Motil 1998; 10: 271-9.
99. Bharucha AE, Camilleri M, Ferber I, Zinsmeister AR. Effects of a serotonin (5-HT4) receptor antagonist on gastrointestinal (GI) transit, colonic motor and sensory function in health. Gastroenterology 1999; 116: A958.
100. Sanger GJ. 5-Hydroxytryptamine and functional bowel disorders. Neurogastroenterol Motil 1996; 8: 319-31.
101. Sanger GJ, Yoshida M, Yahyah M, Kitazumi K. Increased defecation during stress or after 5-hydroxytryptophan: selective inhibition by the 5-HT4 receptor antagonist, SB-207266. Br J Pharmacol 2000; 130: 706-12.
102. Cooper SM, Haydock SF, Tompson DJ, Higgins RG, Fitzpatrick KL. A pharmacodynamic model of 5-HT4 receptor activation in man: antagonism by the 5-HT4 receptor antagonist SB-207266. Gastroenterology 1999; 116: A598.
103. Houghton LA, Jackson NA, Whorwell PJ, Cooper SM. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit. Aliment Pharmacol Ther 1999; 13: 1437-44.
104. Sanger GJ. Hypersensitivity and hyperreactivity in the irritable bowel syndrome: an opportunity for drug discovery. Dig Dis 1999; 17: 90-9.
105. Smith MI, Banner SE, Sanger GJ. 5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats. Neurosci Lett 1999;271:61-4.
106. Coulie B, Tack J, Sifrim D, Andrioli A, Janssens J. Role of nitric oxide in fasting gastric fundus tone and in 5-HT1 receptor-mediated relaxation of gastric fundus. Am J Physiol 1999; 276: G373-7.
107. Coulie B, Tack J, Maes B, Geypens B, De Roo M, Janssens J. Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol 1997; 272: G902-8.
108. Tack J, Coulie B, Wilmer A, Andrioli A, Janssens J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000; 46:468-73.
109. Houghton LA, Fowler P, Keene ON, Read NW. Effect of sumatriptan, a new selective 5HTl-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992; 6: 685-91.
110. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-52.
111. Malatesta MG, Fascetti E, Ciccaglione AF et al. 5-HT 1-receptor agonist sumatriptan modifies gastric size after 500 ml of water in dyspeptic patients and normal subjects. Dig Dis Sci 2002; 47: 2591-5.
112. Sifrim D, Holloway RH, Tack J et al. Effect of sumatriptan, a 5HT1 agonist, on the frequency of transient lower esophageal sphincter relaxations and gastroesophageal reflux in healthy subjects. Am J Gastroenterol 1999; 94: 3158-64.
113. Meulemans AL, Helsen LF, Schuurkes JA. The role of nitric oxide (NO) in 5-HT-induced relaxations of the guinea-pig stomach. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 424-30.
114. De Ponti F, Crema F, Moro E, Nardelli G, Frigo G, Crema A. Role of 5-HT1B/D receptors in canine gastric accommodation: effect of sumatriptan and 5-HT1B/D receptor antagonists. Am J Physiol 2003; 285: G96-104.
115. Moro E, Crema F, De Ponti F, Frigo G. Triptans and gastric accommodation: pharmacological and therapeutic aspects. Dig Liver Dis 2004; 36: 85-92.
116. Meulemans AL, Elsen LF, de Ridder WJA, Schuurkes JAJ. Effects of sumatriptan on the guinea-pig isolated stomach. Neurogastroenterol Motil 1996; 8: A183.
117. Rouzade ML, Fioramonti J, Bueno L. Decrease in gastric sensitivity to distension by 5-HT1A receptor agonists in rats. Dig Dis Sci 1998; 43: 2048-54.
118. Xue L, Locker GRI, Schuurkes JAJ, Meulemans A, Coulie B, Szurszewski JH. Serotonergic modulation of murine fundic tone. Gastroenterology 2003; 124: A580.
119. Janssen P, Prins NH, Moreaux B, Meulemans AL, Lefebvre RA. In vivo characterization of 5-HT1A receptor-mediated gastric relaxation in conscious dogs. Br J Pharmacol 2003; 140: 913-20.
120. Tack J, Piessevaux H, Coulie B, Fischler B, DeGucht VA. Placebo controlled trial of buspirone, a fundus relaxing drug, in functional dyspepsia: effect on symptoms and gastric sensory and motor function. Gastroenterology 1999; 116: G1423.
121. Vanhoenacker P, Haegeman G, Leysen JE. 5-HT7 receptors: current knowledge and future prospects. Trends Pharmacol Sci 2000; 21: 70-7.
122. Carter D, Champney M, Hwang B, Eglen RM. Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum. Eur] Pharmacol 1995; 280: 243-50.
123. Janssen P, Prins NH, Meulemans AL, Lefebvre RA. 5-HT7 receptors mediate canine stomach relaxation, an in vivo study. Neurogastroenterol Motil 2002; 14:571.
124. Janssen P, Prins NH, Meulemans AL, Lefebvre RA. Pharmacological characterization of the 5-HT receptors mediating contraction and relaxation of canine isolated proximal stomach smooth muscle. Br J Pharmacol 2002; 136: 321-9.
125. Tuladhar BR, Ge L, Naylor RJ. 5-HT7 receptors mediate the inhibitory effect of 5-HT on peristalsis in the isolated guinea-pig ileum. Br J Pharmacol 2003; 138: 1210-14.
126. Meuser T, Pietruck C, Gabriel A, Xie GX, Lim KJ, Pierce PP. 5-HT7 receptors are involved in mediating 5-HT-induced activation of rat primary afferent neurons. Life Sci 2002; 71: 2279-89.
127. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santero J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72.
128. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 159-66.
129. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and 1 diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40: 86-95.
130. Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. J. Gut 1998;42:807-13.
131. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-37.
132. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992; 49: 205-19.
133. Tack J, Broekaert D, Coulie B, Fischler B, Janssens J. Influence of the selective serotonin re-uptake inhibitor, paroxet- 1 ine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003; 17: 603-8.
134. Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol 2003; 284: G130-7.
135. Ladabaum U, Glidden D. Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. Neurogastroenterol Motil 2002; 14: 395-102.
136. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 160-5.
137. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219-28.
138. Chial HJ, Camilleri M, Ferber I et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003; 1: 211-18.